Audit a sourcing lane for sole-source exposure. HHI, top-3 share, distinct manufacturers, and the dual-source playbook trigger built in.
Molecule + origin + destination. The AI agent pulls every exporter on the lane and aggregates lane value, shipment count, and per-exporter share.
HHI on the 0-to-1 scale, top-3 cumulative share, distinct manufacturer count. Any lane crossing 0.60 triggers the dual-source workflow with parameters pre-filled.
Citation-anchored brief with the headline KPIs, exporter cohort, time series, and a chip showing the dual-source recommendation.
Lane concentration risk is the moderate-band metric. Sole-source audit is the high-band view, calibrated to the 0.60 to 1.0 range where single-supplier exposure is the dominant risk.
HHI above 0.60 for two consecutive quarters triggers the dual-source candidate workflow. The audit and the remedy are connected at the schema layer.
A lane that was competitive 18 months ago and is now near-monopoly is the worst case. Time series catches the deterioration before the buyer feels it.
Trade aggregates refresh weekly. HHI recomputes on every refresh; the catalog row carries an as-of timestamp.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Eighteen molecule-lanes · HHI on the 0-to-1 scale, 2024 latest year · lanes above 0.60 are auto-flagged.
The sole-source audit is the high-end specialty view on lane concentration. PharmaDB flags lanes with HHI above 0.60, top-3 share above 90 percent, and a thin distinct-manufacturer cohort, then auto-triggers the dual-source workflow. The view rests on lane_competitiveness joined to molecule_country_flow. Refresh cadence is weekly.
Operationally, a lane with HHI above 0.60 on the 0-to-1 scale and top-3 cumulative share above 90 percent. The lane may have multiple named exporters but the supply is functionally controlled by a tight cohort, and disruption to the leader takes the lane offline.
Lane concentration risk is the broader metric (0.25 to 1.0 range). Sole-source audit is the high-end specialty view, with auto-triggered dual-source workflow and a different remediation playbook. Buyers run lane concentration as a routine quarterly scan and sole-source as the deep-dive on the worst lanes.
It pre-fills the dual-source candidate discovery parameters with the molecule, destination, and the existing top exporter, and searches for qualifiable second sources on the same destination from a different origin or a different exporter on the same origin. The companion page is Dual Source Candidate Discovery.
Yes, and that's often the worst-case. The tofacitinib India to US lane at $1.97M annual value is sole-source. Small lanes attract less buyer attention but disruption can still halt a finished-dose programme.
A sole-source lane that is also Chinese-intermediate-dependent is two-stage sole-source: one disruption point at the API plant, another at the KSM plant. The combined view surfaces in the China intermediate dependency map.
Weekly. Trade aggregates refresh weekly. HHI and top-3 share recompute on every refresh; the catalog row carries an as-of timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.